Bone Net Debt To E B I T D A from 2010 to 2024
| BBLGW Stock | USD 27.80 0.00 0.00% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter (7.26) | Current Value (7.62) | Quarterly Volatility 4.47542317 |
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 9.9 M, Ebitda of 503.6 K or Total Operating Expenses of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.43. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
Bone | Net Debt To E B I T D A |
Latest Bone Biologics' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Bone Biologics Corp over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Bone Biologics' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Bone Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | (4.71) | |
| Geometric Mean | 1.72 | |
| Coefficient Of Variation | (95.01) | |
| Mean Deviation | 3.56 | |
| Median | (2.88) | |
| Standard Deviation | 4.48 | |
| Sample Variance | 20.03 | |
| Range | 14.2097 | |
| R-Value | (0.34) | |
| Mean Square Error | 19.03 | |
| R-Squared | 0.12 | |
| Significance | 0.21 | |
| Slope | (0.34) | |
| Total Sum of Squares | 280.41 |
Bone Net Debt To E B I T D A History
About Bone Biologics Financial Statements
Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | (7.26) | (7.62) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bone Stock Analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.